Olitigaltin
Based on 13 publication(s) in Google Scholar
TD139 is a synthetic galectin-3 inhibitor. TD139 has high affinity for galectin-3 with a Kd of 68 nM, a Kd of 0.22 μM for galectin-1, and a Kd of 38 μM for galectin-7.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.74%
- No. CAS: 1450824-22-2
- Fòrmula: C28H30F2N6O8S
- Peso molecular:648.64
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Olitigaltin
More- Autophagy. 2022 May;18(5):1020-1048. [Abstract]
- J Neuroinflammation. 2022 Sep 17;19(1):229. [Abstract]
- Stem Cell Res Ther. 2021 Jul 16;12(1):409. [Abstract]
- Chem Biol Interact. 2022 Dec 1:368:110218. [Abstract]
- Exp Neurol. 2023 Jul:365:114418. [Abstract]
- Cell Signal. 2021 Aug:84:110043. [Abstract]
- J Immunol. 2019 Nov 15;203(10):2712-2723. [Abstract]
- Glycobiology. 2025 Nov 24:cwaf081. [Abstract]
- Brain Res. 2026 Sep 15:1887:150382. [Abstract]
- Patent. US20230273213A1.
- Patent. US20220380473A1.
- Universität zu Köln. 2022 Feb 9.
- Patent. US20220002420A1.
Customer Validation & Images
-
RT-PCR
-
IF
-
In Vivo Imaging
-
ELISA
-
WB
Ver todos los productos específicos de isoformas Galectin
More
Actividad biológica
Kd: 14 nM (galectin-3)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Erythrocyte | IC50 |
0.3 μM
Compound: 6; TD139
|
Inhibition of moues Gal3-induced hemagglutination using mouse RBC incubated for overnight by hemagglutination assay
Inhibition of moues Gal3-induced hemagglutination using mouse RBC incubated for overnight by hemagglutination assay
|
[PMID: 33988358] |
| Monocyte | IC50 |
0.08 μM
Compound: 6; TD139
|
Inhibition of human Gal3-induced chemotaxis using human monocyte incubated for 4 hrs by calcein-AM dye based assay
Inhibition of human Gal3-induced chemotaxis using human monocyte incubated for 4 hrs by calcein-AM dye based assay
|
[PMID: 33988358] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1450824-22-2
-
Appearance Solid
-
Peso molecular 648.64
-
Fòrmula C28H30F2N6O8S
-
Color White to off-white
-
SMILES
O[C@H]([C@@H](N1N=NC(C2=CC=CC(F)=C2)=C1)[C@H]([C@@H](CO)O3)O)[C@@H]3S[C@H]4[C@@H]([C@@H](N5N=NC(C6=CC=CC(F)=C6)=C5)[C@H]([C@@H](CO)O4)O)O
-
Synonyms
TD139; GB0139
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
LGALS3 (galectin 3) mediates an unconventional secretion of SNCA/α-synuclein in response to lysosomal membrane damage by the autophagic-lysosomal pathway in human midbrain dopamine neurons. [Abstract]2022 May;18(5):1020-1048. PMID: 34612142
Olitigaltin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 May;18(5):1020-1048. [Abstract]
Relative fold difference in SNCA from mDA cultured media treated with Olitigaltin (TD139) (5 μM) or vehicle (0.1% DMSO) treated control after 24 h measured by ELISA. The results showed that TD139 treatment significantly reduced SNCA secretion compared to vehicle.
Olitigaltin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 May;18(5):1020-1048. [Abstract]
Representative non-reducing SDS-PAGE of concentrated EVs and the corresponding lysates from mDA neurons treated with vehicle, Olitigaltin (TD139, 1 µM; 24 h), SNCA fibrils, or TD139 + SNCA fibrils.
-
J Neuroinflammation
Genetic targeting or pharmacological inhibition of galectin-3 dampens microglia reactivity and delays retinal degeneration. [Abstract]2022 Sep 17;19(1):229. PMID: 36115971
Olitigaltin purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Sep 17;19(1):229. [Abstract]
Relative mRNA expression of pro-inflammatory cytokines in retinas of naïve and light-exposed mice treated with vehicle or Olitigaltin (TD139, 15 mg/kg; i.p.; once daily) normalized to the reference gene Atp5b. The results showed that following treatment with TD139, the expression levels of iNOS, IL-6, and CCL2—induced by light damage—were also reduced.
Olitigaltin purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Sep 17;19(1):229. [Abstract]
Olitigaltin (TD139, 15 mg/kg; i.p.; once daily) reduced microglia migration in light-exposed retinas. Representative images of Iba-1+ cells in naïve and light-exposed mice treated with vehicle or TD139 at the indicated time points. Scale bar: 50 µm. ONL, outer nuclear layer and INL, inner nuclear layer.
Olitigaltin purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Sep 17;19(1):229. [Abstract]
Olitigaltin (TD139, 15 mg/kg; i.p.; once daily) delayed light-induced retinal degeneration. Representative SD-OCT scans and heat maps of retinal thickness from naïve and light-exposed mice treated with vehicle or TD139. Scale bar: 200 µm.
-
Stem Cell Res Ther
Mesenchymal stem cells ameliorate renal fibrosis by galectin-3/Akt/GSK3β/Snail signaling pathway in adenine-induced nephropathy rat. [Abstract]2021 Jul 16;12(1):409. PMID: 34271976 -
Chem Biol Interact
Inhibition of Galectin-3 attenuates silica particles-induced silicosis via regulating the GSK-3β/β-catenin signal pathway-mediated epithelial-mesenchymal transition. [Abstract]2022 Dec 1:368:110218. PMID: 36223831 -
Exp Neurol
2023 Jul:365:114418. PMID: 37085003 -
Cell Signal
Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPARγ/CD36 signaling pathway. [Abstract]2021 Aug:84:110043. PMID: 33991615 -
J Immunol
Gasdermin D Drives the Nonexosomal Secretion of Galectin-3, an Insulin Signal Antagonist. [Abstract]2019 Nov 15;203(10):2712-2723. PMID: 31597705 -
Glycobiology
Galectin-3 facilitates helicobacter pylori-induced apoptosis independently of sensing lysosomal damage. [Abstract]2025 Nov 24:cwaf081. PMID: 41283852 -
Brain Res
Galectin-3 in microglia mediates neuroinflammation-induced cognitive dysfunction via selective elimination of excitatory synapses in hippocampal CA1. [Abstract]2026 Sep 15:1887:150382. PMID: 42114797 -
-
-
-
Solvente y solubilidad
DMSO : 50 mg/mL (77.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% HP-β-CD in Saline water
Solubility: 3.33 mg/mL (5.13 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 2 mg/mL (3.08 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Mice: The susceptibility to Con A-induced hepatitis in galectin-3-deficient mice is tested and the effects of pretreatment with a selective inhibitor of Gal-3 (TD139) in wild-type(WT) C57BL/6 mice are analyzed, as evaluated by a liver enzyme test, quantitative histology, mononuclear cell (MNC) infiltration, cytokine production, intracellular staining of immune cells, and percentage of apoptotic MNCs in the liver[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Mackinnon AC, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012 Mar 1;185(5):537-46. [Content Brief]
[2]. Volarevic V, et al. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology. 2012 Jun;55(6):1954-64. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5417 mL | 7.7084 mL | 15.4169 mL | 38.5422 mL |
| 5 mM | 0.3083 mL | 1.5417 mL | 3.0834 mL | 7.7084 mL | |
| 10 mM | 0.1542 mL | 0.7708 mL | 1.5417 mL | 3.8542 mL | |
| 15 mM | 0.1028 mL | 0.5139 mL | 1.0278 mL | 2.5695 mL | |
| 20 mM | 0.0771 mL | 0.3854 mL | 0.7708 mL | 1.9271 mL | |
| 25 mM | 0.0617 mL | 0.3083 mL | 0.6167 mL | 1.5417 mL | |
| 30 mM | 0.0514 mL | 0.2569 mL | 0.5139 mL | 1.2847 mL | |
| 40 mM | 0.0385 mL | 0.1927 mL | 0.3854 mL | 0.9636 mL | |
| 50 mM | 0.0308 mL | 0.1542 mL | 0.3083 mL | 0.7708 mL | |
| 60 mM | 0.0257 mL | 0.1285 mL | 0.2569 mL | 0.6424 mL |
Olitigaltin Related Classifications
HY-19940 Related Classifications
Powered by Bioz